2020
DOI: 10.1101/2020.11.16.384438
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Evaluation of saliva as a source of accurate whole-genome and microbiome sequencing data

Abstract: This study sets out to establish the suitability of saliva-based whole-genome sequencing (WGS) through a comparison against blood-based WGS. To fully appraise the observed differences, we developed a novel technique of pseudo-replicates. We also investigated the potential of characterising individual salivary microbiomes from non-human DNA fragments found in saliva.We observed the majority of discordant genotype calls between blood and saliva calls fell into known regions of the human genome that are typically… Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

1
0

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 54 publications
(68 reference statements)
0
1
0
Order By: Relevance
“…The first data set, referred to as MMD‐FREX, consists of whole‐exome sequencing (WES) of cases diagnosed with Moyamoya disease (MMD) and controls from the French general population (French Exome Project—FREX) (Bocher et al, 2021; Guey et al, 2017). The second data set consists of whole‐genome sequencing (WGS) data from blood and saliva samples from the same individuals, this is part of the GAZEL‐ADN project (Herzig et al, 2021). Both datasets are prone to technical bias as the samples are from different projects and sequenced in different laboratories in the case of the MMD‐FREX data, and the samples are from two different tissues and sequenced with two different technologies in the case of the GAZEL‐ADN data.…”
Section: Introductionmentioning
confidence: 99%
“…The first data set, referred to as MMD‐FREX, consists of whole‐exome sequencing (WES) of cases diagnosed with Moyamoya disease (MMD) and controls from the French general population (French Exome Project—FREX) (Bocher et al, 2021; Guey et al, 2017). The second data set consists of whole‐genome sequencing (WGS) data from blood and saliva samples from the same individuals, this is part of the GAZEL‐ADN project (Herzig et al, 2021). Both datasets are prone to technical bias as the samples are from different projects and sequenced in different laboratories in the case of the MMD‐FREX data, and the samples are from two different tissues and sequenced with two different technologies in the case of the GAZEL‐ADN data.…”
Section: Introductionmentioning
confidence: 99%